 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- IPH6501 / Innate
Preclinical Characterization of IPH6501: A Novel IL2v-Armed Tetraspecific NK Cell Engager Targeting CD20 in Relapsed or Refractory B cell Non-Hodgkin Lymphoma Subtypes and Post-CAR-T Therapy. (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1241;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- IPH6501 / Innate
A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma. (Hall A; Poster Bd #: 72a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2430;
P1/2
The Phase 2 part will enroll one or more cohorts of selected B-cell NHL subtypes to be determined at a later stage. Up to 184 subjects will be enrolled, and the study is open in the United States, Australia and Europe.
- IPH6501 / Innate
Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager. (Hall A; Poster Bd #: 13) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2367;
The preclinical demonstrations of IPH6501 activities across various in vivo models and its effectiveness in ex vivo assays using cells from R/R B-NHL patients provide compelling evidence of its therapeutic potential and tolerability. IPH6501 is emerging as a promising new candidate within the treatment landscape for R/R B-NHL and is currently being investigated in a global, first-in-human phase 1/2 study (NCT 06088654).
- ||| IPH6501 / Innate
Enrollment open, Trial initiation date: Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 12, 2024
P1/2, N=184, Recruiting, Sponsor: Innate Pharma
IPH6501 is emerging as a promising new candidate within the treatment landscape for R/R B-NHL and is currently being investigated in a global, first-in-human phase 1/2 study (NCT 06088654). Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Mar 2024
- |||| IPH6501 / Innate
New P1/2 trial: Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 17, 2023
P1/2, N=184, Not yet recruiting, Sponsor: Innate Pharma
- IPH6501 / Innate
IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMAS (Fantasies) - May 12, 2023 - Abstract #EHA2023EHA_2341;
IPH6501 is expected to enter FIH clinical study in 2023. 1.
- | IPH6501 / Innate
I will definitely take IPH65 and get shares of $iph $ipha and secure #Anket platform @sanofi (Twitter) - Jan 12, 2023
- IPH6501 / Innate
IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies () - Nov 29, 2022 - Abstract #ASH2022ASH_7175;
IPH6501 is thus a promising biologic designed to harness the anti-tumor functions of NK cells in CD20+ B cell malignancies. IND-enabling studies are ongoing, and IPH6501 is expected to enter FIH clinical study in 2023.
- tetra-specific ANKET molecule / Innate
Harnessing NK Cell in Cancer Therapies by Antibody-Based NK Cell Engager Therapeutics (ANKET) (306) - Apr 24, 2022 - Abstract #PEGS2022PEGS_476;
We are now reporting on tetra-specific ANKET molecule, which is the first NK cell engager technology to engage two NK cell activating receptors, NKp46 and CD16, a tumor antigen and the interleukin-2 receptor via a single molecule...They had similar pharmacokinetics to IgG1s and no off-target effects. We will present an update on our ANKET platform as a new generation of therapeutic molecules against cancer.